Print PDF

Maureen D. Queler
+1 202 408 4294
maureen.queler@finnegan.com

901 New York Avenue, NW
Washington, DC 20001-4413

+1 202 408 4000
Fax +1 202 408 4400

Bar and Court Admissions

  • District of Columbia
  • Virginia
  • U.S. Court of Appeals, Federal Circuit
  • U.S. Patent and Trademark Office

Education

  • George Washington University Law School
    J.D., high honors, 2008
  • Pennsylvania State University
    B.S., Chemical Engineering, with honors, 2002

Maureen D. Queler

Associate

Maureen Queler practices all aspects of patent-related work in the chemical and pharmaceutical areas, including client counseling, patent prosecution, post-grant proceedings, and U.S. district court and appellate litigation.

Ms. Queler represents clients in inter partes review (IPR) and other contested proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO). She also has an active patent prosecution and counseling practice, preparing and prosecuting U.S. patent applications on behalf of domestic and foreign clients, with an emphasis on chemical subject matter including polymers, cosmetics, pharmaceuticals, oils, renewable diesels, and catalyst technologies. In addition, Ms. Queler has represented pharmaceutical patent holders in federal district court in litigations arising under the Hatch-Waxman Act. She has prepared and examined witnesses in court, taken and defended fact and expert depositions, and conducted and overseen the litigation discovery process.

Ms. Queler devotes time to pro bono matters, representing a number of veterans in appeals before the U.S. Court of Appeals for Veterans Claims.

Highlights

  • Currently defending client in IPR and reexamination proceedings before the PTAB, and appeal proceedings before the Federal Circuit Court of Appeals.
  • Neste Oil Oyj v. REG Synthetic Fuels, LLC (PTAB). Represented Neste Oil as petitioner; PTAB issued final written decision finding unpatentable all of the claims challenged in the petition and denied REG's motion to amend.
  • Pronova Biopharma Norge AS v. Teva Pharmaceuticals USA, Inc. (D. Del.). Represented Pronova in Hatch-Waxman litigation relating to drug Lovaza®.
  • Bilski v. Kappos, (S. Ct.). Assisted with drafting and researching the merits and reply briefs, as well as preparing for oral argument.
  • Former examiner at the USPTO, where she examined applications in all areas of food science and technology including confectionery compositions, packaging, and sterilization processes, 2004-2005.
  • Worked as a vaccine technology engineer for Merck Pharmaceuticals, directly supporting production by optimizing and troubleshooting the vaccine manufacturing process, 2003-2004.

Select Publications